Dissolution Methods for Microsphere and Implant Drug Products

The summary for the Dissolution Methods for Microsphere and Implant Drug Products grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Food and Drug Administration, which is the U.S. government agency offering this grant.
Dissolution Methods for Microsphere and Implant Drug Products: Dissolution testing is recommended as part of the demonstration of bioequivalence between test and reference products in the approval of most generic drugs. Drug release measurements are useful for evaluating the effect of manufacturing differences and to assess performance characteristics of a sustained release dosage form. Generally, a generic drug product intended for parenteral use contains the same inactive ingredients (“Q1”) and in the same concentration (“Q2”) as the Reference Listed Drug (RLD). However, there may be differences in manufacturing of the generic and RLD products, which may affect bioavailability. Dissolution testing can be used as one of several standard methods to evaluate physicochemical differences of the drug product caused by manufacturing differences. The purpose of this study is to investigate dissolution methods for a parenteral sustained release drug product. The results from this study will help the FDA in developing recommendations to determine bioequivalence of generic parenteral sustained release drug products.Objectives:(1) To formulate Q1/Q2 sustained release products (either microspheres or implants) under different manufacturing conditions(2) To conduct dissolution studies with the prepared sustained release formulations using various in vitro release methods(3) To identify a dissolution method that can discriminate different sustained release formulations Detailed Description:Additional details regarding the study objectives listed above:(1) The sustained release formulation chosen to serve as the reference product for this study can either be a marketed product or an investigational formulation. Formulations which are Q1/Q2 to this reference product should be developed under different manufacturing conditions. Physicochemical characterization should be performed on these test formulations to determine key attributes that may affect bioavailability.(2) Before initiating the dissolution studies, an analysis of current dissolution methods used for sustained release products (either microspheres or implants, depending on the dosage form chosen) should be conducted. A report of this analysis should include the advantages and disadvantages for each method and an assessment on the capability of detecting manufacturing differences, predicting in vivo performance, and method robustness. Test formulations which have the largest differences in physicochemical properties (and which are expected to affect bioavailability) are chosen for testing in the dissolution study. Dissolution methods should be developed with considerations in drug substance and drug product properties and the physiological release environment.(3) An analysis of the dissolution methods used in the study should include the advantages and disadvantages for each method and an assessment on the capability of detecting manufacturing differences, predicting in vivo performance, and method robustness.
Federal Grant Title: Dissolution Methods for Microsphere and Implant Drug Products
Federal Agency Name: Food and Drug Administration (HHS-FDA)
Grant Categories: Health Science and Technology
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-FD14-007
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.103
CFDA Descriptions: Information not provided
Current Application Deadline: May 2nd, 2014
Original Application Deadline: May 2nd, 2014
Posted Date: March 31st, 2014
Creation Date: March 31st, 2014
Archive Date: June 1st, 2014
Total Program Funding: $1,000,000
Maximum Federal Grant Award: $500,000
Minimum Federal Grant Award: $400,000
Expected Number of Awards: 5
Cost Sharing or Matching: No
Last Updated: April 7th, 2014
Applicants Eligible for this Grant
State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility
Foreign Recipients
Link to Full Grant Announcement
NIH Guide for Grants and Contracts
Grant Announcement Contact
Gladys Melendez-Bohler
Grants Management Specialist
Phone 301-827-7175
FDA Office
Similar Government Grants
Development and Maintenance of the Animal Food Regulatory Program Standards (U19) Clinical...
Use of Digital Health Technologies in Clinical Investigations to Support Drug and Biologic...
Cooperative Agreement to Support the World Trade Organization's (WTO) Standards and Trade ...
Cooperative Agreement for Long Term Data Collection on Antimicrobial Use in Animals (U01) ...
Alliance to Support the Activities of the Integrated Food Safety System (IFSS), including ...
Support for Small Scientific Conference Grant Program
Cooperative Agreement to Support the World Health Organization (WHO) International Program...
Clinical Studies of Safety and Effectiveness of Orphan Products
More Grants from the Food and Drug Administration
Development and Maintenance of the Animal Food Regulatory Program Standards (U19) Clinical...
Use of Digital Health Technologies in Clinical Investigations to Support Drug and Biologic...
Cooperative Agreement to Support the World Trade Organization's (WTO) Standards and Trade ...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com